Provided by Tiger Trade Technology Pte. Ltd.

NeoGenomics

7.96
-0.2200-2.69%
Volume:3.31M
Turnover:26.45M
Market Cap:1.03B
PE:-9.44
High:8.24
Open:8.15
Low:7.86
Close:8.18
52wk High:13.74
52wk Low:4.72
Shares:129.39M
Float Shares:119.99M
Volume Ratio:2.39
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8433
EPS(LYR):-0.8433
ROE:-12.42%
ROA:-2.90%
PB:1.23
PE(LYR):-9.44

Loading ...

How NeoGenomics' Q3 Results and Liquid Biopsy Advances Will Impact NEO Investors

Simply Wall St.
·
Nov 09, 2025

NeoGenomics Inc. to Participate in Stephens Annual Investment Conference

Reuters
·
Nov 06, 2025

NEO Battery Secures $3M Order and Advances Facility Lease

TIPRANKS
·
Nov 06, 2025

NEO has been leading the way in the robotics field. What projects in the Robotic space are worth paying attention to?

Blockbeats
·
Oct 31, 2025

NeoGenomics to present RaDaR ST bridging study at ISLB 2025

TIPRANKS
·
Oct 31, 2025

NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection

Reuters
·
Oct 31, 2025

Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target

Stock Track
·
Oct 29, 2025

Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target

Stock Track
·
Oct 29, 2025

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

TIPRANKS
·
Oct 29, 2025

NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges

TIPRANKS
·
Oct 29, 2025

Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target

TIPRANKS
·
Oct 29, 2025

NeoGenomics’ Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

TIPRANKS
·
Oct 29, 2025

Stock Track | NeoGenomics Soars 10.24% as Q3 Results Beat Expectations, Driven by Strong Clinical Revenue Growth

Stock Track
·
Oct 28, 2025

Stock Track | NeoGenomics Soars 7.28% Pre-Market on Strong Q3 Results, Beating Revenue Estimates

Stock Track
·
Oct 28, 2025

GUIDANCE: (NEO) NeoGenomics Expects Full Year 2025 Consolidated Revenue Range $720M - $726M, vs. FactSet Est of $723.5M

MT Newswires Live
·
Oct 28, 2025

Cancer diagnostics company NeoGenomics beats Q3 estimates on clinical revenue growth

Reuters
·
Oct 28, 2025

NeoGenomics Q3 Adj. EPS $0.03 Beats $0.02 Estimate, Sales $187.797M Beat $183.770M Estimate

Benzinga
·
Oct 28, 2025

BRIEF-NeoGenomics Q3 Revenue USD 188 Million Vs. IBES Estimate USD 183.8 Million

Reuters
·
Oct 28, 2025

Neogenomics Inc: Re-Affirming Full-Year Guidance for Revenue, Net Loss and Adjusted Ebitda

THOMSON REUTERS
·
Oct 28, 2025

Neogenomics Q3 Gross Profit USD 80 Million

THOMSON REUTERS
·
Oct 28, 2025